UID:
almahu_9949890729302882
Format:
1 online resource
ISBN:
9780415000383
,
0415000386
,
9780429275906
,
0429275900
,
9781000000382
,
1000000389
,
9781000013740
,
100001374X
,
9781000007213
,
1000007219
Content:
There is a new trend in anti-cancer therapeutics development: a targeted therapy and precision medicine that targets a subgroup of patients with specific biomarkers. An in vitro diagnostic (IVD) assay is required to identify a subgroup of cancer patients who would benefit from the targeted therapy, or not likely benefit, or have a high risk of side effects from the specific drug treatment. This IVD or medical device is called a companion diagnostic (CDx) assay. It is key to have a robust CDx assay or device for the success of targeted therapy and precision medicine. This book covers the technical, historical, clinical, and regulatory aspects of CDx in precision medicine. Clearly, more and more newly developed oncology drugs will require accompanying CDx assays, and this book, with chapters contributed by renowned oncologists, provides a comprehensive foundation for the knowledge and application of CDx for precision medicine.
Note:
Overview of companion diagnostics (CDx) For precision medicine -- Companion diagnostic (CDx) tests in clinical laboratory improvement amendments (CLIA)-certified laboratories -- Quantitative polymerase chain reaction for companion diagnostics and precision medicine application -- Protein biomarker signatures in precision diagnostics of cancer -- Next-generation sequencing (NGS) for companion diagnostics (CDx) and precision medicine.
Additional Edition:
Print version: Companion diagnostics (CDx) in precision medicine. Singapore : Pan Stanford Publishing, 2019 ISBN 9814800236
Additional Edition:
ISBN 9789814800235
Language:
English
DOI:
10.1201/9780429275906
URL:
https://www.taylorfrancis.com/books/9780429275906
Bookmarklink
